Updates are available Correction dated 2018-11-15
Click to view Correction: https://doi.org/10.1038/s41582-018-0077-9
-
Authors
Wells, Elizabeth
Hacohen, Yael
Waldman, Amy
Tillema, Jan M.
Soldatos, Ariane
Ances, Beau
Benseler, Susanne
Bielekova, Bibi
Dale, Russel C.
Dalmau, Josep
Gaillard, William
Gorman, Mark
Greenberg, Benjamin
Hyslop, Ann
Pardo, Carlos A.
Tasker, Robert C.
Yeh, E. Ann
Bar-Or, Amit
Pittock, Sean
Vanderver, Adeline
Banwell, Brenda
,
Carpenter, Jessica
Cortese, Irene
Dean, Nathan
Farias-Moeller, Racquel
Gallentine, William
Glaser, Carol
Goldbach-Mansky, Raphaela
Kahn, Ilana
Lavenstein, Bennett
McClintock, William
McDow, William
Murphy, Jennifer
Nath, Avindra
Packer, Roger
Ronis, Tova
Schleyer, David
Schleyer, Stephanie
Shibuya, Peter
Utz, Ursula
Vezina, Gilbert
Wessel, David
- License Information
-
More Information
Article History
First Online: 20 June 2018
Change Date: 15 November 2018
Change Type: Correction
Change Details: In the original version of this Review published online and in print, the contribution of attendees of the International Neuroimmune Meeting to the content of the Review was not acknowledged. The author list has been corrected in the PDF and HTML versions of this article to acknowledge that the Review was written on behalf of attendees of the International Neuroimmune Meeting, and the names of the attendees have been added to the HTML version.
Competing interests
: A.W. has received research support from Biogen, Chugai, MedImmune, Ionis Pharmaceuticals and Novartis. She has also received speaker’s fees from SUNY Downstate Medical Center and receives publishing royalties from UpToDate. R.C.D. has received research funding from Pfizer and Star Scientific Foundation. He has also received honoraria from Biogen and Bristol-Myers Squibb as an invited speaker. W.G. sits on the editorial board of <i>Epilepsia</i> and holds stock from Eli Lilly, General Electric, GlaxoSmithKline, Johnson and Johnson, Pfizer and Siemens. M.G. has received grant support from Lilly, Novartis, Sobi and Regeneron. B.G. serves on the medical and scientific advisory board of the Transverse Myelitis Association. He has received consulting income from EMD Serono and Novartis. He has grant support from Acorda Therapeutics, Biogen, Chugai and MedImmune. C.A.P. serves on the medical and scientific advisory board of the Transverse Myelitis Association. E.A.Y. has received speaker’s honoraria from EXCEMED, and she is an ACI consultant. S.P. and the Mayo Clinic have a financial interest in patents (#12/678,350 filed in 2010 and #12/573,942 filed in 2008) that relate to functional aquaporin 4 immunoglobulin (IgG) and neuromyelitis optica IgG assays and neuromyelitis optica IgG as a cancer marker. S.P. has consulted for Alexion Pharmaceuticals, Chugai and MedImmune but has received no personal fees or personal compensation for these consulting activities; all compensation for consulting activities is paid directly to the Mayo Clinic. He has also received a research grant from Alexion Pharmaceuticals for an investigator-initiated study. All other authors declare no competing interests.
